Literature DB >> 24744220

Development of EUCAST zone diameter breakpoints and quality control range for Staphylococcus aureus with ceftaroline 5-μg disk.

L M Koeth1, E Matuschek, G Kahlmeter, R A Alm, J E Ambler.   

Abstract

This ceftaroline MIC/disk comparison study for Staphylococcus aureus was performed for the purpose of establishing EUCAST zone diameter breakpoints. Ceftaroline susceptibility for a challenge set of 70 methicillin resistant- and 30 methicillin susceptible-S. aureus was determined by 5-μg disk diffusion and broth microdilution methods. Seventeen isolates were retested by disk and MIC, and the remaining 83 isolates were retested by MIC. Molecular testing was performed on 19 isolates with borderline susceptible ceftaroline MIC results to assess any differences in mecA and epidemiological correlation. An additional set of 101 consecutive clinical S. aureus isolates were tested using the 5-μg disk. S. aureus ATCC 29213 was tested by multiple sites and media for QC range determination. Replicate MIC results were within ±1 doubling dilution, with tendency for slightly lower repeat MICs, and there was minimal variation in replicate zone results. Based on susceptible breakpoints for MIC of ≤1 mcg/mL and for disk of >20 mm, there was 100 % categorical agreement for 30 MSSA and 92 % categorical agreement for 70 MRSA. There were no common MLST or PBP changes for strains with MICs of 1 and 2 mcg/mL. All ceftaroline disk results for the consecutively collected isolates were >20 mm. EUCAST selected the ceftaroline 5-μg disk breakpoint of Susceptible ≥20, Resistant <20 mm because it correlated best with the MIC breakpoint of Susceptible ≤1, Resistant >1 mg/L. A ceftaroline 5-μg disk QC range for S. aureus ATCC 29213 of 24-30 mm was also established by EUCAST.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24744220     DOI: 10.1007/s10096-014-2089-8

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  2 in total

1.  Characterization of methicillin-resistant Staphylococcus aureus displaying increased MICs of ceftaroline.

Authors:  Rodrigo E Mendes; Athanassios Tsakris; Helio S Sader; Ronald N Jones; Donald Biek; Pamela McGhee; Peter C Appelbaum; Klaudia Kosowska-Shick
Journal:  J Antimicrob Chemother       Date:  2012-03-07       Impact factor: 5.790

2.  Spectrum and potency of ceftaroline tested against leading pathogens causing community-acquired respiratory tract infections in Europe (2010).

Authors:  David J Farrell; Robert K Flamm; Ronald N Jones; Helio S Sader
Journal:  Diagn Microbiol Infect Dis       Date:  2012-11-10       Impact factor: 2.803

  2 in total
  1 in total

1.  Missense mutations in PBP2A Affecting ceftaroline susceptibility detected in epidemic hospital-acquired methicillin-resistant Staphylococcus aureus clonotypes ST228 and ST247 in Western Switzerland archived since 1998.

Authors:  William L Kelley; Ambre Jousselin; Christine Barras; Emmanuelle Lelong; Adriana Renzoni
Journal:  Antimicrob Agents Chemother       Date:  2015-01-12       Impact factor: 5.191

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.